Results 201 to 210 of about 4,342,004 (341)

Complement-activating lectin, RaRF.

Nippon Saikingaku Zasshi, 1999
openaire   +3 more sources

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Blood, 2017
M. Harder, Nadine Kuhn, H. Schrezenmeier, B. Höchsmann, I. von Zabern, C. Weinstock, T. Simmet, Daniel Ricklin, John D Lambris, A. Skerra, M. Anliker, C. Schmidt   +11 more
semanticscholar   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Complement Activation in BK Polyoma Virus Nephropathy: What's the Story? [PDF]

Kidney Int Rep
Stokes MB.
europepmc   +1 more source

Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

, 1978
Robert D. Schreiber, Michael K. Pangburn, Philippe Lesavre, Hans J. Müller‐Eberhard   +3 more
openalex   +2 more sources

Quantitative Characterization of the Activation Steps of Mannan-binding Lectin (MBL)-associated Serine Proteases (MASPs) Points to the Central Role of MASP-1 in the Initiation of the Complement Lectin Pathway [PDF]

, 2013
Márton Megyeri, Veronika Harmat, Balázs Major, Ádám Végh, Júlia Balczer, Dávid Héja, Katalin Szilágyi, Dániel Datz, Gábor Pál, Péter Závodszky, Péter Gál, József Dobó   +11 more
openalex   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Role of local complement activation in kidney fibrosis and repair. [PDF]

J Clin Invest
Portilla D, Sabapathy V, Chauss D.
europepmc   +1 more source

Complement activity and vitamin C [PDF]

Biochemical Journal, 1943
E. Kodicek, B. Traub
openaire   +2 more sources

Monitoring of complement activation biomarkers and eculizumab in complement‐mediated renal disorders

Clinical and Experimental Immunology, 2017
C. Wehling, Oliver Amon, Martin Bommer, Bernd Hoppe, Karim Kentouche, Gesa Schalk, R. Weimer, M. Wiesener, Bernd Hohenstein, B. Tönshoff, Rainer Büscher, H. Fehrenbach, Ömer-Necmi Gök, M. Kirschfink   +13 more
semanticscholar   +1 more source